Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-02C: Tiragolumab + Atezolizumab + CE in Untreated ES-SCLC
NCT04665856Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tiragolumab + Atezolizumab + Carboplatin and Etoposide with Placebo + Atezolizumab + Carboplatin and Etoposide (2 arms). Primary endpoints: Progression-Free Survival at 32.3 months and Overall Survival at 32.3 months. Started Dec 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04665856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665856.